A Single-Center, Randomized, Double Blind, Placebo-Controlled, Crossover Evaluation of the Effect of GXR as Adjunctive Treatment With Stimulant on Executive Function and Quality of Life at Home and School in Children With ADHD
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2016
Price : $35 *
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 15 May 2016 Protocol has been amended to change in treatment table.
- 15 May 2016 Status changed from recruiting to completed.
- 26 Nov 2013 New trial record